Idelalisib Alternatives Compared
| Idelalisib | Epkinly (epcoritamab) | Rituximab |
|
|---|
| Idelalisib | Epkinly (epcoritamab) | Rituximab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoma, Non-Hodgkin's Lymphoma. Idelalisib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma. Epkinly may also be used for purposes not listed in this medication guide. |
Prescription only
Rituximab (brand name Rituxan) is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia... View more |
||||||||
| More about Idelalisib | More about Epkinly (epcoritamab) | More about Rituximab | ||||||||
| Ratings & Reviews | ||||||||||
|
Idelalisib has an average rating of 4.5 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 50% reported a negative effect. |
Be the first to share your experience with this drug. |
Rituximab has an average rating of 7.8 out of 10 from a total of 163 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Epkinly prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Zydelig |
N/A |
Riabni, Rituxan, Ruxience, Truxima | ||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
8.2 hours |
528 hours |
59.8 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 874 drugs are known to interact with Idelalisib:
|
A total of 239 drugs are known to interact with Epkinly:
|
A total of 176 drugs are known to interact with Rituximab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
July 23, 2014 |
May 19, 2023 |
N/A |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.